Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856881 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT01856881 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 86 participants.
The verdict
NCT01856881, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
Interventions
- DRUG AMG 876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01856881
The ClinicalTrials.gov registry entry for NCT01856881 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 876 is the first listed.
NCT01856881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01856881 about?
NCT01856881 is a clinical study titled "Multiple Ascending Dose Study in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
What is the current status of trial NCT01856881?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2013-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01856881?
The interventions under investigation include: AMG 876 (DRUG).
Who is sponsoring clinical trial NCT01856881?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.